NCT02912325View on ClinicalTrials.gov

Non-Comparative Study to Assess the Efficacy and Safety of the New Food Supplement FaseMETS

NACompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 9, 2017

Primary Completion Date

October 15, 2017

Study Completion Date

June 11, 2018

Conditions
Metabolic Syndrome
Interventions
DIETARY_SUPPLEMENT

Daily administration: 2 tablets FaseMETS a day

Treatment with FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome

Trial Locations (2)

300209

Opera Contract Research Organization SRL, Timișoara

Scm Dr Rosu, Timișoara

All Listed Sponsors
collaborator

Opera CRO, a TIGERMED Group Company

OTHER

lead

MDM S.p.A.

OTHER

NCT02912325 - Non-Comparative Study to Assess the Efficacy and Safety of the New Food Supplement FaseMETS | Biotech Hunter | Biotech Hunter